Mechanism of action of niacin on lipoprotein metabolism

[1]  L. Carlson.  Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. , 2009, Acta medica Scandinavica.

[2]  J. Hokanson,et al.  Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. , 1999, Circulation.

[3]  V. Kamanna,et al.  Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[4]  K. Cianflone,et al.  Role of cholesterol ester mass in regulation of secretion of ApoB100 lipoprotein particles by hamster hepatocytes and effects of statins on that relationship. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[5]  A. Tall,et al.  Decreased Atherosclerosis in Heterozygous Low Density Lipoprotein Receptor-deficient Mice Expressing the Scavenger Receptor BI Transgene* , 1999, The Journal of Biological Chemistry.

[6]  M. Kashyap.  Mechanistic studies of high-density lipoproteins. , 1998, The American journal of cardiology.

[7]  P. Kwiterovich.  State-of-the-art update and review: clinical trials of lipid-lowering agents. , 1998, The American journal of cardiology.

[8]  A. Tall,et al.  Liver-specific Overexpression of Scavenger Receptor BI Decreases Levels of Very Low Density Lipoprotein ApoB, Low Density Lipoprotein ApoB, and High Density Lipoprotein in Transgenic Mice* , 1998, The Journal of Biological Chemistry.

[9]  G. Fonarow,et al.  High density associated enzymes: their role in vascular biology. , 1998, Current opinion in lipidology.

[10]  J. Fruchart,et al.  Selective uptake of cholesteryl esters from high-density lipoprotein-derived LpA-I and LpA-I:A-II particles by hepatic cells in culture. , 1998, Biochimica et biophysica acta.

[11]  J. Higgins,et al.  Regulation of the assembly and secretion of very low density lipoproteins by the liver. , 1998, Biological chemistry.

[12]  J. Liao,et al.  Endothelium and acute coronary syndromes. , 1998, Clinical chemistry.

[13]  J. Hokanson,et al.  Lipoprotein classes and coronary disease regression. , 1998, Current opinion in lipidology.

[14]  C. Packard,et al.  Heterogeneity of apolipoprotein B-100-containing lipoproteins: what we have learnt from kinetic studies. , 1998, Current opinion in lipidology.

[15]  A. Tall,et al.  Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Gotto,et al.  Effects of lipid lowering therapy on progression of coronary and carotid artery disease. , 1997, Current opinion in lipidology.

[17]  A. Rigotti,et al.  A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  V. Kamanna,et al.  Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[19]  E. Edelman,et al.  Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels , 1997, Nature.

[20]  V. Kamanna,et al.  Atherogenic lipoproteins and human disease: extending concepts beyond the heart to the kidney. , 1997, Current opinion in nephrology and hypertension.

[21]  H. Jamil,et al.  An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Banka.  High density lipoprotein and lipoprotein oxidation , 1996, Current opinion in lipidology.

[23]  D. Rader,et al.  Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models , 1996, Current opinion in lipidology.

[24]  D. Steinberg.  A Docking Receptor for HDL Cholesterol Esters , 1996, Science.

[25]  Helen H. Hobbs,et al.  Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.

[26]  Roger A. Davis,et al.  In HepG2 Cells, Translocation, Not Degradation, Determines the Fate of the de Novo Synthesized Apolipoprotein B * , 1995, The Journal of Biological Chemistry.

[27]  J. Gamble,et al.  High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[28]  H. Ginsberg.  Synthesis and secretion of apolipoprotein B from cultured liver cells , 1995, Current opinion in lipidology.

[29]  M. Katan,et al.  Nutrition and therapeutics: where we are and where we should be going. , 1995 .

[30]  C. Fielding,et al.  Molecular physiology of reverse cholesterol transport. , 1995, Journal of lipid research.

[31]  R. Krauss.  Heterogeneity of plasma low‐density lipoproteins and atherosclerosis risk , 1994, Current opinion in lipidology.

[32]  X. Wu,et al.  Evidence for a lack of regulation of the assembly and secretion of apolipoprotein B-containing lipoprotein from HepG2 cells by cholesteryl ester. , 1994, The Journal of biological chemistry.

[33]  M. Gimbrone,et al.  Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. , 1994, The Journal of clinical investigation.

[34]  X. Wu,et al.  Proteolysis and lipid-facilitated translocation are distinct but competitive processes that regulate secretion of apolipoprotein B in Hep G2 cells. , 1993, The Journal of biological chemistry.

[35]  E. Rubin,et al.  Protein composition determines the anti-atherogenic properties of HDL in transgenic mice , 1993, Nature.

[36]  J. Qiao,et al.  Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. , 1993, Science.

[37]  K. Messmer,et al.  Stimulation of leukocyte/endothelium interaction by oxidized low-density lipoprotein in hairless mice. Involvement of CD11b/CD18 adhesion receptor complex. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[38]  H. Ginsberg,et al.  Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. , 1993, Journal of lipid research.

[39]  N. Sakata,et al.  Studies of the sites of intracellular degradation of apolipoprotein B in Hep G2 cells. , 1992, The Journal of biological chemistry.

[40]  M. Cybulsky,et al.  Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. , 1992, The Journal of clinical investigation.

[41]  W. J. Johnson,et al.  Cholesterol efflux from cells to immunopurified subfractions of human high density lipoprotein: LP-AI and LP-AI/AII. , 1991, Journal of lipid research.

[42]  A. J. Valente,et al.  Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. , 1991, The Journal of clinical investigation.

[43]  R. Krauss,et al.  Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI , 1991, Nature.

[44]  H. Ginsberg,et al.  Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. , 1991, The Journal of biological chemistry.

[45]  S. Kouidou,et al.  Synergistic interactions between transcription factors control expression of the apolipoprotein AI gene in liver cells , 1991, Molecular and cellular biology.

[46]  K. Cianflone,et al.  Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. , 1990, Journal of lipid research.

[47]  F. Parhami,et al.  Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[48]  C. Bisgaier,et al.  Characterization of apoA-I-containing lipoprotein subpopulations secreted by HepG2 cells. , 1989, Journal of lipid research.

[49]  M. Kashyap.  Basic considerations in the reversal of atherosclerosis: significance of high-density lipoprotein in stimulating reverse cholesterol transport. , 1989, The American journal of cardiology.

[50]  J. Steinberg.  Book ReviewAmbulatory Pediatric Care , 1989 .

[51]  H. Brewer,et al.  Tissue-specific expression of apolipoprotein A-I (ApoA-I) is regulated by the 5'-flanking region of the human ApoA-I gene. , 1988, The Journal of biological chemistry.

[52]  R. Davis,et al.  Intrahepatic assembly of very low density lipoproteins. Rate of transport out of the endoplasmic reticulum determines rate of secretion. , 1987, The Journal of biological chemistry.

[53]  J. Fruchart,et al.  Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. , 1987, Biochemical and biophysical research communications.

[54]  J. Neaton,et al.  Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.

[55]  J. Borén,et al.  Pulse-chase studies of the synthesis and intracellular transport of apolipoprotein B-100 in Hep G2 cells. , 1986, The Journal of biological chemistry.

[56]  R. Ross.  The pathogenesis of atherosclerosis--an update. , 1986, The New England journal of medicine.

[57]  J. Kane,et al.  Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[58]  C. Packard,et al.  Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. , 1979, The Journal of clinical investigation.

[59]  N. Le,et al.  Direct measurement of apoprotein B specific activity in 125I-labeled lipoproteins. , 1978, Journal of lipid research.

[60]  C. Blum,et al.  High density lipoprotein metabolism in man. , 1977, The Journal of clinical investigation.

[61]  R. Ellis,et al.  Some insulin-like effects of nicotinic acid observed with isolated rat epididymal adipose tissue. , 1961, Biochimica et biophysica acta.

[62]  T. Carew,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[63]  S. Grundy,et al.  Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. , 1981, Journal of lipid research.

[64]  M. Brown,et al.  Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. , 1979, Proceedings of the National Academy of Sciences of the United States of America.